Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zomedica Corp. (ZOM)
|
Add to portfolio |
|
|
|
| Price: |
$0.35
| | Metrics |
| OS: |
979.9
|
M
| |
-7
|
% ROE
|
| Market cap: |
$343
|
M
| |
-18
|
% ROIC
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
($0.02)
| |
|
|
|
BVPS
|
$0.26
| |
1.32
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 18.9 | 4.1 | 0.0 | 39.1 | 33.2 | 16.2 | 11.5 |
| Revenue growth | 358.0% | | -100.0% | 17.5% | 105.5% | 41.2% | |
| Cost of goods sold | 5.3 | 1.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 13.7 | 3.1 | 0.1 | 39.1 | 33.2 | 16.2 | 11.5 |
| Gross margin | 72.1% | 73.9% | | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 33.0 | 22.8 | 8.7 | | | | |
| Research and development | 2.6 | 1.7 | 8.0 | 10.3 | 10.3 | 2.8 | 1.5 |
| General and administrative | | | | 8.7 | 6.1 | 5.2 | 4.2 |
| EBITA | -18.3 | -20.7 | -16.4 | 19.8 | 16.7 | 8.1 | 5.7 |
| EBITA margin | -96.7% | -502.0% | | 50.7% | 50.1% | 50.0% | 50.0% |
| Amortization of intangibles | 3.6 | 0.9 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT | -21.9 | -21.6 | -16.6 | 19.8 | 16.6 | 8.1 | 5.7 |
| EBIT margin | -115.8% | -523.2% | | 50.7% | 50.1% | 50.0% | 50.0% |
| Pre-tax income | -19.4 | -20.7 | -16.9 | 19.8 | 16.6 | 8.1 | 5.7 |
| Income taxes | -2.4 | -2.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 12.2% | 11.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -17.0 | -18.4 | -16.9 | 19.8 | 16.6 | 8.1 | 5.7 |
| Net margin | -89.9% | -444.8% | | 50.7% | 50.1% | 49.9% | 50.1% |
| |
| Diluted EPS | ($0.02) | ($0.02) | ($0.05) | $0.19 | $0.18 | $0.09 | $0.07 |
| Shares outstanding (diluted) | 979.9 | 956.5 | 364.4 | 106.3 | 93.4 | 87.4 | 80.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|